| GeoVax, Inc. |
Medicine Pharmaceuticals
COVID-19 vaccine
GeoVax uses GV-MVA-VLPTM vaccine platform and expertise to design and construct vaccine candidates using genetic sequences from the ongoing COVID-2019 outbreak. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The GV-MVA-VLPTM derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while typically providing the safety characteristics of a replication-defective vector.
In the preclinical evaluation/regulatory stage
